Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 18:10:151.
doi: 10.3389/fonc.2020.00151. eCollection 2020.

Gross Total vs. Subtotal Resection on Survival Outcomes in Elderly Patients With High-Grade Glioma: A Systematic Review and Meta-Analysis

Qian Han  1 , Hengpo Liang  1 , Peng Cheng  1 , Hongjie Yang  1 , Pingfan Zhao  2
Affiliations

Gross Total vs. Subtotal Resection on Survival Outcomes in Elderly Patients With High-Grade Glioma: A Systematic Review and Meta-Analysis

Qian Han et al. Front Oncol. .

Abstract

Background: The optimal strategy for the management of high-grade glioma in the elderly (≥60.0 years) remains controversial, especially regarding the effects of surgical extent on survival outcomes. The purpose of this study was to compare gross total resection (GTR) with subtotal resection (STR) for treatment effects in elderly patients with high-grade glioma. Methods: Three electronic databases were systematically searched, including PubMed, EmBase, and the Cochrane library, from inception to August 2018. Hazard ratios (HRs) or odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were used to express summary effect estimates using the random-effects model. Nineteen retrospective observational studies involving a total of 10,815 elderly patients with high-grade glioma were included in this meta-analysis. Results: The summary results indicated that GTR was associated with a significant improvement in overall survival (OS) compared with STR (HR = 0.70, 95% CI = 0.64-0.77). In addition, elderly patients administered GTR showed lower risk of 3-month mortality (OR = 0.47, 95% CI = 0.24-0.93), 6-month mortality (OR = 0.38, 95% CI = 0.26-0.56), 9-month mortality (OR = 0.35, 95% CI = 0.25-0.49), and 1-year mortality (OR = 0.40, 95% CI = 0.29-0.56). Pooled OS data differed when stratified by publication year, country, sample size, disease status, and study quality. Conclusion: GTR seems to be more effective than STR in achieving longer survival in elderly patients with high-grade glioma.

Keywords: elderly patients; gross total resection; high-grade glioma; meta-analysis; mortality; subtotal resection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart of the literature search and study selection processes.
Figure 2
Figure 2
Therapeutic effects of gross total resection (GTR) and subtotal resection (STR) on overall survival (OS) in elderly patients with high-grade glioma.
Figure 3
Figure 3
Therapeutic effects of gross total resection (GTR) and subtotal resection (STR) on 3-month mortality in elderly patients with high-grade glioma.
Figure 4
Figure 4
Therapeutic effects of gross total resection (GTR) and subtotal resection (STR) on 6-month mortality in elderly patients with high-grade glioma.
Figure 5
Figure 5
Therapeutic effects of gross total resection (GTR) and subtotal resection (STR) on 9-month mortality in elderly patients with high-grade glioma.
Figure 6
Figure 6
Therapeutic effects of gross total resection (GTR) and subtotal resection (STR) on 1-year mortality in elderly patients with high-grade glioma.
See this image and copyright information in PMC

References

    1. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol. (2015) 17(Suppl. 4):iv1–62. 10.1093/neuonc/nov189 - DOI - PMC - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. (2005) 352:987–96. 10.1056/NEJMoa043330 - DOI - PubMed
    1. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. . A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. (2014) 370:699–708. 10.1056/NEJMoa1308573 - DOI - PMC - PubMed
    1. Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, et al. . Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. (2012) 48:1532–42. 10.1016/j.ejca.2011.12.013 - DOI - PubMed
    1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. (2009) 10459–66. 10.1016/S1470-2045(09)70025-7 - DOI - PubMed

Publication types

LinkOut - more resources